← Back to Search

Anti-metabolites

Shorter Chemo-Immunotherapy Without Anthracyclines for Breast Cancer

Phase 3
Recruiting
Led By Priyanka Sharma
Research Sponsored by SWOG Cancer Research Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must not have a history of (non-infectious) pneumonitis that required steroids, or has current (non-infectious) pneumonitis
Participants must be >= 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial compares shorter chemo-immunotherapy without anthracyclines to usual chemo-immunotherapy to treat early-stage triple negative breast cancer. Drugs used to stop cancer cells from growing/dividing & kill them, plus an immunotherapy drug.

Who is the study for?
This trial is for adults with early-stage triple negative breast cancer who haven't had systemic or radiation therapy, or breast surgery for their current cancer. They must have good heart function and no severe allergies to the study drugs. Participants can't be pregnant/nursing and must agree to use contraception. No live vaccines 30 days before joining, no uncontrolled diseases like diabetes or hypertension, and they shouldn't have a history of certain infections or other cancers that could affect the trial.Check my eligibility
What is being tested?
The trial tests if shorter chemo-immunotherapy without anthracycline drugs (like Doxorubicin) is as effective as usual treatment in early-stage triple negative breast cancer. It involves medications such as Paclitaxel, Carboplatin, Cyclophosphamide, Docetaxel, and Pembrolizumab which target different aspects of cancer cell growth.See study design
What are the potential side effects?
Possible side effects include fatigue; hair loss; nausea; low blood counts leading to increased infection risk; nerve damage causing numbness or tingling; allergic reactions; heart problems from some chemotherapy drugs; immune-related issues like inflammation from Pembrolizumab.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have never needed steroids for non-infectious lung inflammation.
Select...
I am 18 years old or older.
Select...
I haven't had severe infections or been hospitalized for one in the last 14 days.
Select...
Both of my breast cancers are negative for ER, PR, and HER2.
Select...
My cancer has not spread to distant parts of my body.
Select...
My heart is strong enough for the trial, with an ejection fraction of 50% or more.
Select...
I am not on high-dose steroids or other drugs that weaken my immune system.
Select...
I can provide a specific slide from my initial cancer diagnosis.
Select...
I haven't had a live vaccine in the last 30 days.
Select...
I have not had surgery on the breast currently affected by cancer.
Select...
I haven't had any treatment aimed at curing my current breast cancer.
Select...
I had hepatitis C but am now cured, or I am being treated with undetectable levels.
Select...
My nerve damage symptoms are mild or not present.
Select...
I have not been treated with specific immune therapy drugs before.
Select...
I can take care of myself and am up and about more than 50% of my waking hours.
Select...
My cancer is at a specific stage and has not spread to distant parts of my body.
Select...
I have had a biopsy to check the status of my lymph nodes.
Select...
My breast cancer is triple-negative.
Select...
My breast cancer is not at an advanced stage with significant lymph node involvement.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Breast cancer event-free survival (BC-EFS)
Secondary outcome measures
Distant relapse-free interval (DRFI)
Distant relapse-free survival (DRFS)
Incidence of adverse events
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (shorter chemo-immunotherapy)Experimental Treatment7 Interventions
Patients receive docetaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial.
Group II: Arm I (usual chemo-immunotherapy)Active Control9 Interventions
Patients receive paclitaxel IV, carboplatin IV, and pembrolizumab IV on study. Patients then receive doxorubicin IV, cyclophosphamide IV, and pembrolizumab IV on study. Patients then undergo surgery. Patients may receive pembrolizumab after surgery. Patients may optionally undergo collection of blood samples throughout the trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Docetaxel
1995
Completed Phase 4
~5620
Surgical Procedure
2020
Completed Phase 2
~160
Biospecimen Collection
2004
Completed Phase 2
~1720
Carboplatin
2014
Completed Phase 3
~6670
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

SWOG Cancer Research NetworkLead Sponsor
395 Previous Clinical Trials
262,748 Total Patients Enrolled
54 Trials studying Breast Cancer
65,326 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,957,001 Total Patients Enrolled
944 Trials studying Breast Cancer
1,544,008 Patients Enrolled for Breast Cancer
Priyanka SharmaPrincipal InvestigatorSWOG Cancer Research Network

Media Library

Cyclophosphamide (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT05929768 — Phase 3
Breast Cancer Research Study Groups: Arm II (shorter chemo-immunotherapy), Arm I (usual chemo-immunotherapy)
Breast Cancer Clinical Trial 2023: Cyclophosphamide Highlights & Side Effects. Trial Name: NCT05929768 — Phase 3
Cyclophosphamide (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05929768 — Phase 3
~1600 spots leftby Mar 2033